Evidence map›Paper›PMID 26315834›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2015

Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib.

Sarah E Bohndiek, Laura S Sasportas, Steven Machtaler, Jesse V Jokerst, Sharon Hori, Sanjiv S Gambhir

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Current trends in the characterization and monitoring of vascular response to cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sarah E BohndiekBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California.
Laura S SasportasBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California.
Steven MachtalerBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California.
Jesse V JokerstBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California.
Sharon HoriBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California.
Sanjiv S GambhirBio-X Program and Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California sgambhir@stanford.edu.
Stanford University · US

Funding

Pilot ProjectsU54CA151459 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2010 to 2014
$12.6M
VECTOR COREP30NS069375 · NINDS · STANFORD UNIVERSITY · PI STEINBERG, GARY K · 2011 to 2019
$6.3M
Vevo LAZR Photoacoustic Imaging SystemS10OD021821 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALL, DAVID J · 2016 to 2016
$594k
A Therapeutic Tool for ULtrasound-Guided Stem Cell TherapyK99HL117048 · NHLBI · STANFORD UNIVERSITY · PI JOKERST, JESSE VINCENT · 2014 to 2015
$265k
NCI NIH HHS U54 CA151459NHLBI NIH HHS K99 HL117048NINDS NIH HHS NS069375NINDS NIH HHS P30 NS069375
6 · The paper itself

Abstract

unlabelledThe primary aim of this study was to assess the potential of in vivo photoacoustic tomography for direct functional measurement of ovarian tumor response to antiangiogenic therapy.

methodsIn vivo studies were performed with institutional animal care and use committee approval. We used an orthotopic mouse model of ovarian cancer treated with trebananib (n = 9) or vehicle (n = 9). Tumor-bearing mice were randomized into trebananib or vehicle groups at day 10 and dosed on days 12, 15, and 18 after implantation. Photoacoustic tomography and blood draws were performed at day 10 and then 24 h after each drug dose. Tumors were excised for histopathology after the final studies on day 19. Data analysis to test for statistical significance was performed blinded.

resultsBlockade of angiopoietin signaling using trebananib resulted in reduced total hemoglobin-weighted photoacoustic signal (n = 9, P = 0.01) and increased oxyhemoglobin-weighted photoacoustic signal (n = 9, P < 0.01). The latter observation indicated normalization of the residual tumor vessels, which was also implied by low levels of angiopoietin 1 in serum biomarker profiling (0.76 ± 0.12 ng/mL). These noninvasive measures reflected a 30% reduction in microvessel density and increased vessel maturation in ex vivo sections.

conclusionPhotoacoustic tomography is able to evaluate both vessel regression and normalization in response to trebananib. Noninvasive imaging data were supported by modulation of serum markers in vitro and ex vivo histopathology.

Indexed as

Angiogenesis InhibitorsAngiopoietin-1AnimalsBlood VesselsCell Line, TumorFemaleHemoglobinsHumansImage Processing, Computer-AssistedLuminescenceMiceOvarian NeoplasmsPhotoacoustic TechniquesRecombinant Fusion ProteinsRegional Blood FlowAngiogenesis InhibitorsAngiopoietin-1HemoglobinsRecombinant Fusion Proteinstrebananibangiogenesisangiopoietinovarian cancerphotoacoustics

Identifiers

PMID26315834
PMCPMC5612481
OpenAlexW2183266787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.